Restricted accessResearch articleFirst published online 2025-11
Understanding the relationship between patient-reported outcome measures,clinician-rated assessments,and performance-based measures (cognitive tests and device-based estimates) of symptoms and functioning in people with Huntington's disease
Given the progressive cognitive decline in Huntington's disease (HD), most research in this population relies solely on objective assessments of symptoms and function, rather than on patient-reported outcome (PRO) measures.
Objective
The purpose of this paper is to understand how PRO measures relate to clinician-rated assessments and performance-based measures (cognitive tests and device-based estimates) of symptoms and functioning in people with HD.
Methods
We enrolled N = 52 participants with HD in this study. Participants completed several self-reported PROs as well as clinician-administered assessments and performance-based measures (cognitive tests and device-based estimates) of related concepts. Pearson correlations and linear regression models were used to examine the concordance among PROs, clinician-rated assessments, and performance-based measures.
Results
There were strong relationships among PROs that assessed related concepts. There were also strong relationships between PROs and associated clinician-rated assessments of physical functioning (chorea, sleep/fatigue) and mental health, and slightly less robust relationships between the PROs and associated clinician-rated assessments for speech/swallowing and cognition. Relationships between PROs and associated performance-based measures were moderate for chorea/motor functioning, but negligible for sleep/fatigue and cognition.
Conclusions
Findings from this study support the construct validity of PROs that assess motor functioning and mental health among individuals with HD and indicate that PROs and clinician-rated assessments of these constructs (i.e., motor functioning and mental health) provide complementary information. On the other hand, the negligible relationships between PROs and associated performance-based cognitive tests and between PROs and associated wearable device-based estimates of sleep and physical activity indicate that reliance solely on HD patients’ self-report for these concepts might be misleading.
DuffKPaulsenJMillsJ, et al.Mild cognitive impairment in prediagnosed Huntington disease. Neurology2010; 75: 500–507.
2.
SnowdenJCraufurdDGriffithsH, et al.Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc2001; 7: 33–44.
3.
PaulsenJSReadyREHamiltonJM, et al.Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry2001; 71: 310–314.
4.
DuffKPaulsenJSBeglingerLJ, et al.Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry2007; 62: 1341–1346.
5.
LongJDPaulsenJSMarderK, et al.Tracking motor impairments in the progression of Huntington's disease. Mov Disord2014; 29: 311–319.
6.
MaroofDAGrossALBrandtJ. Modeling longitudinal change in motor and cognitive processing speed in presymptomatic Huntington's disease. J Clin Exp Neuropsychology2011; 33: 901–909.
7.
TabriziSJScahillRIDurrA, et al.Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol2011; 10: 31–42.
8.
TabriziSJLangbehnDRLeavittBR, et al.Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol2009; 8: 791–801.
9.
PaulsenJSLongJDJohnsonHJ, et al.Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci2014; 6: 78.
10.
PaulsenJSZhaoHStoutJC, et al.Clinical markers of early disease in persons near onset of Huntington's disease. Neurology2001; 57: 658–662.
11.
PeavyGMJacobsonMWGoldsteinJL, et al.Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord2010; 25: 1163–1169.
12.
BeglingerLJDuffKAllisonJ, et al.Cognitive change in patients with Huntington disease on the repeatable battery for the assessment of neuropsychological Status. J Clin Exp Neuropsychol2010; 32: 573–578.
13.
StoutJCJonesRLabuschagneI, et al.Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry2012; 83: 687–694.
14.
WilliamsJKKimJIDowningN, et al.Everyday cognition in prodromal Huntington disease. Neuropsychology2015; 29: 255–267.
15.
WardJSheppardJMShpritzB, et al.A four-year prospective study of cognitive functioning in Huntington's disease. J Int Neuropsychol Soc2006; 12: 445–454.
TabriziSJReilmannRRoosRA, et al.Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol2012; 11: 42–53.
18.
HoAKSahakianBJBrownRG, et al.Profile of cognitive progression in early Huntington's disease. Neurology2003; 61: 1702–1706.
19.
KirkwoodSCSuJLConneallyP, et al.Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol2001; 58: 273–278.
20.
EkströmMChangSJohnsonMJ, et al.Low agreement between mMRC rated by patients and clinicians: implications for practice. Eur Respir J2019; 54: 1901517.
21.
CarlozziNESchillingSKratzAL, et al.Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?Qual Life Res2018; 27: 2541–2555.
22.
CarlozziNEBoileauNRPerlmutterJS, et al.Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. J Neurol2018; 265: 1443–1453.
23.
BaschEIasonosAMcDonoughT, et al.Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol2006; 7: 903–909.
24.
BreamECharmanSCCliftB, et al.Relationship between patients’ and clinicians’ assessments of health status before and after knee arthroplasty. Qual Saf Health Care2010; 19: e6.
25.
GaoKWuRWangZ, et al.Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder. J Psychiatr Res2015; 60: 117–124.
26.
BaandrupLRasmussenJOMainzJ, et al.Patient-reported outcome measures in mental health clinical research: a descriptive review in comparison with clinician-rated outcome measures. Int J Qual Health Care2022; 34: ii70–ii97.
27.
PowersJHIIIHowardKSaretskyT, et al.Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis2016; 63(Suppl 2): S52–S56.
28.
PowersJHIIIPatrickDLWaltonMK, et al.Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health2017; 20: 2–14.
29.
HanauerDAMeiQLawJ, et al.Supporting information retrieval from electronic health records: a report of university of Michigan's nine-year experience in developing and using the electronic medical record search engine (EMERSE). J Biomed Inform2015; 55: 290–300.
30.
CarlozziNETroostJPMinerJA, et al.Daily variation in symptoms and functioning in Huntington disease: feasibility and variability. Parkinsonism Relat Disord2025; 133: 107346.
31.
Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord1996; 11: 136–142.
32.
ShoulsonIKurlanRRubinAJ. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: MunsatTL (ed) Quantification of neurological deficit. Boston: Butterworths, 1989, pp.271–283.
SmithA. Symbol digit modalities test: Manual. Los Angeles: Western Psychological Services, 1982.
35.
TombaughTNKozakJReesL. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol1999; 14: 167–177.
36.
GoldenCJFreshwaterSMSyzdekB, et al.Stroop color and word test normative update. Wood Dale, Illinois: Stelting Company, 2022.
37.
StroopJR. Studies of interference in serial verbal reactions (reprinted from journal experimental-psychology, vol 18, pg 643–662, 1935). J Exp Psychol Gen1992; 121: 15.
38.
ATSCommittee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med2002; 166: 111–117; Erratum in Am J Respir Crit Care Med 2016; 193: 1185.
Ancoli-IsraelSMartinJLBlackwellT, et al. The SBSM guide to actigraphy monitoring: clinical and research applications. Behav Sleep Med2015; 13(Suppl 1): S4–S38.
41.
CarlozziNEDowningNRSchillingSG, et al.The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Qual Life Res2016; 25: 2429–2439.
42.
CarlozziNEBoileauNRChouKL, et al.HDQLIFE And neuro-QoL physical function measures: responsiveness in persons with huntington's disease. Mov Disord2020; 35: 326–336.
43.
CarlozziNSchillingSGLaiJ-S, et al. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res2016; 25: 212–225.
44.
BuysseDJYuLMoulDE, et al.Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep2010; 33: 781–792.
45.
CellaDFNowinskiCPetermanA, et al. The neurology quality of life measurement (neuro-QOL) initiative. Arch Phys Med Rehab2011; 92(10 Suppl): S28–S36.
46.
CellaDLaiJSNowinskiCJ, et al.Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology2012; 78: 1860–1867.
47.
CarlozziNESchillingSGLaiJS, et al.HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, speech difficulties, and swallowing difficulties. Qual Life Res2016; 25: 2417–2427.
48.
CarlozziNESchillingSGLaiJS, et al.HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res2016; 25: 2441–2455.
49.
CarlozziNEBoileauNRRobertsA, et al.Understanding speech and swallowing difficulties in individuals with Huntington disease: validation of the HDQLIFE speech difficulties and swallowing difficulties item banks. Qual Life Res2021; 30: 251–265.
50.
BodeRKHahnEADeVellisR, et al.Measuring participation: the patient-reported outcomes measurement information system experience. Arch Phys Med Rehabil2010; 91: S60–S65.
51.
CellaDYountSRothrockN, et al.The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care2007; 45: S3–S11.
52.
TabriziSJSchobelSGantmanEC, et al.A biological classification of Huntington's disease: the integrated staging system. Lancet Neurol2022; 21: 632–644.
53.
CudneyLEFreyBNMcCabeRE, et al.Investigating the relationship between objective measures of sleep and self-report sleep quality in healthy adults: a review. J Clin Sleep Med2022; 18: 927–936.
54.
AiliKAstrom-PaulssonSStoetzerU, et al.Reliability of actigraphy and subjective sleep measurements in adults: the design of sleep assessments. J Clin Sleep Med2017; 13: 39–47.
55.
BilterysTVan LooverenEMalflietA, et al.Relationship, differences, and agreement between objective and subjective sleep measures in chronic spinal pain patients with comorbid insomnia: a cross-sectional study. Pain2023; 164: 2016–2028.
56.
KlierKWagnerM. Agreement of sleep measures-a comparison between a sleep diary and three consumer wearable devices. Sensors (Basel)2022; 22: 6189.
57.
De FrancescoDSabinCAWinstonA, et al.Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals. Aids2021; 35: 1051–1060.
58.
SchokmanABinYSSimonelliG, et al.Agreement between subjective and objective measures of sleep duration in a low-middle income country setting. Sleep Health2018; 4: 543–550.
59.
LaiJSGoodnightSDowningNR, et al.Evaluating cognition in individuals with Huntington disease: neuro-QoL cognitive functioning measures. Qual Life Res2018; 27: 811–822.
60.
HughesSBChurchillESmirnovaA, et al.Anosognosia in HD: comparison of self-report and caregiver ratings with objective performance measures. Parkinsonism Relat Disord2023; 107: 105272.
61.
RockPLRoiserJPRiedelWJ, et al.Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med2014; 44: 2029–2040.
62.
HutchinsonADHoskingJRKichenadasseG, et al.Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev2012; 38: 926–934.
63.
HarrisMBlancoEHowieH, et al.The discrepancy between subjective and objective evaluations of cognitive and functional ability among people with schizophrenia: a systematic review. Behav Sci (Basel)2023; 14: 30.
64.
BurmesterBLeathemJMerrickP. Subjective cognitive complaints and objective cognitive function in aging: a systematic review and meta-analysis of recent cross-sectional findings. Neuropsychol Rev2016; 26: 376–393.
65.
ChatterjeeAAndersonKEMoskowitzCB, et al.A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci2005; 17: 378–383.
